Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?

References

• McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med.334(1), 1–6 (1996).
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol.21(17), 3194–3200 (2003).
   PubMed Web of Science ®Google Scholar
• Green TH Jr. Hemisulfur mustard in the palliation of patients with metastatic ovarian carcinoma. Obstet. Gynecol.13(4), 383–393 (1959).
   PubMed Web of Science ®Google Scholar
• Suhrland LG, Weisberger AS. Intracavitary 5-fluorouracil in malignant effusions. Arch. Intern. Med.116, 431–433 (1965).
   PubMed Web of Science ®Google Scholar
• Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. JAMA159(18), 1704–1707 (1955).
   PubMed Web of Science ®Google Scholar
• Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep.62(1), 1–11 (1978).
   PubMedGoogle Scholar
• Winter WE 3rd, Maxwell GL, Tian C et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol.25(24), 3621–3627 (2007).
   PubMed Web of Science ®Google Scholar
• Hoskins WJ, McGuire WP, Brady MF et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol.170(4), 974–949; discussion 979–980 (1994).
   PubMed Web of Science ®Google Scholar
• Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol. Oncol.(2), 159–166 (1992).
   Google Scholar
• Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW, McVie JG. Direct diffusion of cis-diamminedichloroplatinum (II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res.49(12), 3380–3384 (1989).
   PubMed Web of Science ®Google Scholar
• Los G, Mutsaers PH, Ruevekamp M, McVie JG. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother. Pharmacol.25(6), 389–394 (1990).
   PubMed Web of Science ®Google Scholar
• Howell SB, Zimm S, Markman M et al. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J. Clin. Oncol.5(10), 1607–1612 (1987).
   PubMed Web of Science ®Google Scholar
• Kirmani S, Lucas WE, Kim S et al. A Phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma. J. Clin. Oncol.9(4), 649–657 (1991).
   PubMed Web of Science ®Google Scholar
• Barakat RR, Sabbatini P, Bhaskaran D et al. Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J. Clin. Oncol.20(3), 694–698 (2002).
   PubMed Web of Science ®Google Scholar
• Markman M, Brady MF, Spirtos NM et al. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J. Clin. Oncol.16(8), 2620–2624 (1998).
   PubMed Web of Science ®Google Scholar
• Rothenberg ML, Liu PY, Braly PS et al. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup Phase II trial. J. Clin. Oncol.21(7), 1313–1319 (2003).
   PubMed Web of Science ®Google Scholar
• Kirmani S, Braly PS, McClay E et al. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol. Oncol.54(3), 338–344 (1994).
   PubMed Web of Science ®Google Scholar
• Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med.335(26), 1950–1955 (1996).
   PubMed Web of Science ®Google Scholar
• Polyzos A, Tsavaris N, Kosmas C et al. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology56(4), 291–296 (1999).
   PubMed Web of Science ®Google Scholar
• Gadducci A, Carnino F, Chiara S et al. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol. Oncol.76(2), 157–162 (2000).
   PubMed Web of Science ®Google Scholar
• Markman M, Bundy BN, Alberts DS et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol.19(4), 1001–1007 (2001).
   PubMed Web of Science ®Google Scholar
• Yen MS, Juang CM, Lai CR, Chao GC, Ng HT, Yuan CC. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int. J. Gynaecol. Obstet.72(1), 55–60 (2001).
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med.354(1), 34–43 (2006).
   PubMed Web of Science ®Google Scholar
• Shapiro F, Schneider J, Markman M et al. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up. Gynecol. Oncol.67(1), 39–45 (1997).
   PubMed Web of Science ®Google Scholar
• Wrigley E, Weaver A, Jayson G et al. A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: a comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals. Ann. Oncol.7(7), 705–711 (1996).
   PubMed Web of Science ®Google Scholar
• Gore M, Mainwaring P, A’Hern R et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J. Clin. Oncol.16(7), 2426–2434 (1998).
   PubMed Web of Science ®Google Scholar
• McGuire WP, Hoskins WJ, Brady MF et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol.13(7), 1589–1599 (1995).
   PubMed Web of Science ®Google Scholar
• Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J. Clin. Oncol.13(12), 2961–2967 (1995).
   PubMed Web of Science ®Google Scholar
• Markman M, Rowinsky E, Hakes T et al. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J. Clin. Oncol.10(9), 1485–1491 (1992).
   PubMed Web of Science ®Google Scholar
• Walker JL, Armstrong DK, Huang HQ et al. Intraperitoneal catheter outcomes in a Phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol. Oncol.100(1), 27–32 (2006).
   PubMed Web of Science ®Google Scholar
• Trimble EL, Christian MC. Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma. Gynecol. Oncol.100(1), 3–4 (2006).
   PubMed Web of Science ®Google Scholar
• Naumann RW, Sukumvanich P, Edwards RP. Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer. Gynecol. Oncol.108, S22 (2008) (Abstract 47).
   Google Scholar
• Gore M, du Bois A, Vergote I. Intraperitoneal chemotherapy in ovarian cancer remains experimental. J. Clin. Oncol.24(28), 4528–4530 (2006).
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bookman MA, Young RC. Intraperitoneal chemotherapy for ovarian cancer. N. Engl. J. Med.354(15), 1641–1643; Author reply 1641–1643 (2006).
   PubMed Web of Science ®Google Scholar
• du Bois A, Lück HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl Cancer Inst.95(17), 1320–1329 (2003).
   PubMed Web of Science ®Google Scholar
• Alberts DS, Delforge A. Maximizing the delivery of intraperitoneal therapy while minimizing drug toxicity and maintaining quality of life. Semin. Oncol.33(6 Suppl. 12), S8–S17 (2006).
   Web of Science ®Google Scholar
• Muggia F. More on intraperitoneal therapy. Gynecol. Oncol.103(2), 763 (2006).
   PubMed Web of Science ®Google Scholar
• Elferink F, van der Vijgh WJ, Klein I et al. Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother. Pharmacol.21(1), 57–60 (1988).
   PubMed Web of Science ®Google Scholar
• Los G, Verdegaal EM, Mutsaers PH et al. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother. Pharmacol.28(3), 159–165 (1991).
   PubMed Web of Science ®Google Scholar
• Miyagi Y, Fujiwara K, Kigawa J et al. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin – a Sankai Gynecology Study Group (SGSG) study. Gynecol. Oncol.99(3), 591–596 (2005).
   PubMed Web of Science ®Google Scholar
• DeGregorio MW, Lum BL, Holleran WM, Wilbur BJ, Sikic BI. Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a Phase I study of the Northern California Oncology Group. Cancer Chemother. Pharmacol.18(3), 235–238 (1986).
   PubMed Web of Science ®Google Scholar
• Speyer JL, Beller U, Colombo N et al. Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy. J. Clin. Oncol.8(8), 1335–1341 (1990).
   PubMed Web of Science ®Google Scholar
• Speyer JL, Sorich J. Intraperitoneal carboplatin: rationale and experience. Semin. Oncol.19(1 Suppl. 2), 107–113 (1992).
   PubMedGoogle Scholar
• Markman M, Reichman B, Hakes T et al. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer. Gynecol. Oncol.50(1), 100–104 (1993).
   PubMed Web of Science ®Google Scholar
• Bookman MA, McGuire WP III, Kilpatrick D et al. Carboplatin and paclitaxel in ovarian carcinoma: a Phase I study of the Gynecologic Oncology Group. J. Clin. Oncol.14(6), 1895–1902 (1996).
   PubMed Web of Science ®Google Scholar
• McClay EF, Braly PD, Kirmani S et al. A Phase II trial of intraperitoneal high-dose carboplatin and etoposide with granulocyte macrophage-colony stimulating factor support in patients with ovarian carcinoma. Am. J. Clin. Oncol.18(1), 23–26 (1995).
   PubMed Web of Science ®Google Scholar
• Fujiwara K, Sakuragi N, Suzuki S et al. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol. Oncol.90(3), 637–643 (2003).
   PubMed Web of Science ®Google Scholar
• Fujiwara K, Suzuki S, Ishikawa H, Oda T, Aotani E, Kohno I. Preliminary toxicity analysis of intraperitoneal carboplatin in combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube. Int. J. Gynecol. Cancer15(3), 426–431 (2005).
   PubMed Web of Science ®Google Scholar
• Fujiwara SN, Kigawa J, Noma J et al. Comparative Phase II study of intraperitoneal (IP) versus intravenous (IV) carboplatin administration with IV paclitaxel in patients with bulky residual disease after primary debulking surgery for epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Study Group (SGSG) study. J. Clin. Oncol.2007 ASCO Annual Meeting Proceedings Part I, 25(18S), 5584(a) (2007).
   Web of Science ®Google Scholar
• Howell SB, Pfeifle CL, Wung WE et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann. Intern. Med.97(6), 845–851 (1982).
   PubMed Web of Science ®Google Scholar
• Krasner CN, Seiden MV, Fuller AF et al.; Dana Farber/Harvard Cancer Center. Pharmacokinetic analysis of an all intraperitoneal carboplatin and paclitaxel regimen in ovarian cancer patients demonstrates favorable systemic bioavailability of both agents. J. Clin. Oncol.2006 ASCO Annual Meeting Proceedings Part I, 24(18S), 5008(a) (2006).
   Google Scholar
• Morgan RJ Jr, Doroshow JH, Synold T et al. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin. Cancer Res.9(16 Pt 1), 5896–5901 (2003).
   PubMed Web of Science ®Google Scholar
• Vasey PA, Jayson GC, Gordon A et al. Phase III randomized trial of docetaxel–carboplatin versus paclitaxel–carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl Cancer Inst.96(22), 1682–1691 (2004).
   PubMed Web of Science ®Google Scholar
• Krasner CN, Seiden MV, Fuller AF et al.; Dana-Farber/Harvard Cancer Center Gynecologic Oncology Research Group. Results of all-intraperitoneal carboplatin and paclitaxel regimen shows good tolerability and efficacy for advanced ovarian cancer. J. Clin. Oncol.2007 ASCO Annual Meeting Proceedings Part I, 25(18S), 5521(a) (2007).
   Web of Science ®Google Scholar
• Alberts DS, Markman M, Muggia F et al. Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer. Gynecol. Oncol.103(3), 783–792 (2006).
   PubMed Web of Science ®Google Scholar
• Markman M, Walker JL. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J. Clin. Oncol.24(6), 988–994 (2006).
   PubMed Web of Science ®Google Scholar
• Davidson SA, Rubin SC, Markman M et al. Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system. Gynecol. Oncol.41(2), 101–106 (1991).
   PubMed Web of Science ®Google Scholar
• Makhija S, Leitao M, Sabbatini P et al. Complications associated with intraperitoneal chemotherapy catheters. Gynecol. Oncol.81(1), 77–81 (2001).
   PubMed Web of Science ®Google Scholar
• Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D. Baseline quality of life (QOL) as a predictor of tolerance to intraperitoneal (IP) chemotherapy for advanced epithelial ovarian cancer (EOC): a Gynecologic Oncology Group (GOG) study. J. Clin. Oncol.2006 ASCO Annual Meeting Proceedings Part I. 24(18S), 5007(a) (2006).
   Google Scholar